Results for tag: "Alirocumab"

Alirocumab is a monoclonal antibody used to treat cardiovascular diseases. It is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, which works by blocking the action of PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein (LDL) cholesterol from the blood. Alirocumab is used to reduce the risk of cardiovascular events, such as heart attack and stroke, in adults with established cardiovascular disease or with familial hypercholesterolemia. It is also used to reduce LDL cholesterol levels in adults with primary hyperlipidemia. Alirocumab is administered as an injection under the skin, usually once every two weeks. Common side effects include injection site reactions, upper respiratory tract infections, and muscle pain. The Alirocumab market is a rapidly growing segment of the cardiovascular drugs market. It is a relatively new drug, and its use is expected to increase as more people become aware of its benefits. It is also expected to be used in combination with other drugs to treat cardiovascular diseases. Companies in the Alirocumab market include Sanofi, Regeneron Pharmaceuticals, Amgen, and Pfizer. Show Less Read more